Condition
Myxoid/Round Cell Liposarcoma
Total Trials
5
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
5Total
P 1 (4)
P 2 (1)
Trial Status
Terminated2
Withdrawn1
Recruiting1
Active Not Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06083883Phase 1Recruiting
Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
NCT05120271Phase 1Active Not Recruiting
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
NCT03399448Phase 1Terminated
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
NCT02609984Phase 2Terminated
Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)
NCT02059850Phase 1Withdrawn
NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Showing all 5 trials